AZD3229 is primarily utilized in the field of oncology research, where it serves as a potent inhibitor targeting specific kinases involved in cancer cell proliferation and survival. Its application is crucial in preclinical studies aimed at understanding the mechanisms of tumor growth and resistance to therapy. Researchers employ AZD3229 to evaluate its efficacy in suppressing kinase activity, thereby inhibiting the signaling pathways that drive cancer progression. This compound is also used in combination studies with other therapeutic agents to explore synergistic effects and enhance treatment outcomes. Additionally, AZD3229 plays a significant role in the development of targeted therapies, offering potential for more precise and effective cancer treatments with reduced side effects compared to traditional chemotherapy. Its use in animal models helps assess pharmacokinetics, pharmacodynamics, and safety profiles, paving the way for potential clinical trials.